Excellent points Skint. Interestingly the p values for the CDR-SB and the MMSE even with the data finessing are still barely statistically significant (p<0.05) for the highest does (10mg) that resulted in 38% drop outs. Compare those results to the repeated TMTB results that were highly statistically significant in the REACH2HD and 2A trials.
Paper Alert: Aducanumab Phase 1b Study Published, page-4
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.879K | 2.590M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 79758033 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 1157860 | 1 |
View Market Depth
| Last trade - 15.57pm 17/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |